Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

POST-MARKETING SURVEILLANCE STUDY TO OBSERVE INLYTA (REGISTERED) TREATMENT DOSING PATTERN, SAFETY AND EFFECTIVENESS IN TAIWAN REAL WORLD ROUTINE PRACTICE

NCT02533258 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02533258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02533258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
POST-MARKETING SURVEILLANCE STUDY TO OBSERVE INLYTA (REGISTERED) TREATMENT DOSING PATTERN, SAFETY AND EFFECTIVENESS IN TAIWAN REAL WORLD ROUTINE PRACTICE
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
December 2, 2015
Completion date
May 12, 2016
Enrollment
13 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma